We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Sony
Augustine
sony-rose.augustine@mft.nhs.uk
Hannah
Frost
Hannah.frost@cruk.manchester.ac.uk
Tariq
Aslam
tariq.aslam@manchester.ac.uk
Visual disturbances and blindnessComplications of surgical and medical care, not elsewhere classifiedMalignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Many cancer patients with advanced disease enter clinical trials when they have exhausted all available standard treatments. These early phase clinical trials involve giving innovative new drugs with unknown side effects to cancer patients. These include side effects, or toxicities, which impact the eyes. In some cases these can lead to visual changes, including blindness, that may indicate how toxic these new drugs are, or a potential response to treatment. In many cases, there is very little preplanning or management plans put in place for the detection of eye toxicities in advance of patients commencing on a clinical trial. Additionally, the expertise of eye specialists is not always available to all patients undergoing cancer treatment, and they may only be referred to eye specialists when symptoms and signs of eye toxicity become more apparent and advanced. This leads to delays in identification, treatment and follow-up management. Access to this expertise would help in detecting these often unpredictable eye toxicities, however, current demands on resources means that this expertise is not readily available. Developing an artificial intelligence (AI) algorithm trained in the detection of cancer related eye toxicities will go a significant way in easing the burden on the health care system, and improving side effects from new cancer therapies.
This study, sponsored by The University of Manchester, will involve the collection of patient data and copies of the images produced when patients undergo an Optical Coherence Tomography (OCT) scan of the eyes at Manchester Royal Eye Hospital. This data and the copy images will be used to develop and assess AI methods to detect eye abnormalities associated with cancer treatment, and to compare these methods with the assessments of ophthalmologists, to assess if the AI methods give similar results.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
1. Cataracts or prior history of cataracts.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Hannah
Frost
Hannah.frost@cruk.manchester.ac.uk
Tariq
Aslam
tariq.aslam@manchester.ac.uk
Sony
Augustine
sony-rose.augustine@mft.nhs.uk
The study is sponsored by University of Manchester and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 48286
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
